

Treatment of nasal inflammation in children using azithromycin alone or combined with lactulose.

Submission date 20/02/2019	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 22/02/2019	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 21/02/2019	Condition category Respiratory	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and aims:

Antibiotics are necessary to fight infections especially in children. Unfortunately antibiotics do not only kill bad bacteria – but also affect commensal flora (beneficial bacteria), important to good health. An effect of antibiotics, is depletion of commensal flora and a loss of this protective barrier, that leaves them exposed to a vast variety of diseases.

This study researches if commensal bacteria can benefit during the administration of antibiotics when a prebiotic (Lactulose) is given during treatment. Lactulose, a flora nourishment is expected to allow commensal flora to survive the treatment delivering a more beneficial treatment approach with less adverse effects.

Who can participate?

Children of both sexes, between 3 and 14 years of age, diagnosed with Acute Purulent Sinusitis were included. All subjects had provided written informed consent (signed by parent/guardian) and have agreed not to take other prebiotics, probiotics, synbiotics, and/or sorbents during the course of the study.

What does the study involve?

Patients with diagnosis of Acute Purulent Sinusitis have been treated with antibiotic. Group 1 - with azithromycin plus lactulose (food for beneficial bacteria), one dose a day during three days; Group 2 – with azithromycin, one dose a day during three days. Patients provided stool before and after the treatment, and the stool was analysed on composition of beneficial or pathogenic bacteria.

What are the possible benefits and risks of participating?

Benefits were free treatment, even in the case of leaving/dropping out of the study and contribution to research.

Risks were expected possible adverse events, common and uncommon for the used antibiotic.

Where is the study run from?

This study run only in a single centre in Moscow and took place in Clinical Center 1, Children's City Polyclinic No. 133 of the Department of Health of Moscow.

When is the study starting and how long is it expected to run for?

Study had started on 21st of April, 2015 and ended on 25th of January, 2016.

Who is funding the study?

MC Development, Russia.

Who is the main contact?

Dr Christos Shamas, c.shamas@avvapharma.com

Contact information

Type(s)

Scientific

Contact name

Dr Christos Shamas

ORCID ID

<http://orcid.org/0000-0001-7295-6587>

Contact details

23A, Spyrou Kyprianou

Mesa Yitonia

Limassol

Cyprus

4001

+357 25 572200

c.shamas@avvapharma.com

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

ECOMED-11/2014

Study information

Scientific Title

An open, randomized comparative study of the efficacy and safety of using Ecomed (powder for oral suspension, containing azithromycin 100mg/5ml and lactulose 200mg/5ml, manufactured by JSC AVVA RUS, Russia) compared with Sumamed (powder for suspension, containing azithromycin 100mg/5ml, by Pliva Hrvatska doo, Croatia) in children with rhinosinusitis.

Acronym

ECOMED

Study objectives

Comparative evaluation of the clinical efficacy of Ecomed and Sumamed in children with rhinosinusitis.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 19/01/2015, Local Committee for Research Ethics, (55 Smolnaya str. 125445, Moscow, Russia; +7 (495) 456-32-03; dgp133medved@yandex.ru), ref: GBUZ "DGP No. 133 DZM"

Study design

An open, randomized, single-centre, comparative study of the efficacy and safety of drugs when administered to children with rhinosinusitis.

Primary study design

Interventional

Secondary study design

Randomised parallel trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use contact details to request a participant information sheet.

Health condition(s) or problem(s) studied

Rhinosinusitis in children

Interventions

Dosage regimens:

Ecomed is a powder for suspension, containing 100mg of azithromycin/5ml and 200mg of lactulose/5ml (JSC AVVA RUS, Russia);

Sumamed - suspension powder containing 100mg of azithromycin/5ml (Pliva Hrvatska doo, Republic of Croatia).

Method of administration: administration of oral suspension 1 time per day at the dose of 10mg /kg/day and 20mg/kg/day lactulose, where applicable.

Treatment duration: 3 days.

Observation period: 60 days \pm 2 days.

Duration of participation of one patient in the study: 68 days (screening 3 days + 3 days of therapy and + 60 \pm 2 days observation period).

The randomization sequences were produced by web-based free randomization resource <https://www.randomizer.org/>. The study includes screening period, randomization period, period of treatment and monitoring (follow-up). During the research study, 4 visits are conducted: visit 1-screening; visit 2-randomization and start of treatment (baseline); visit 3-completion of treatment (day 3), visit 4- follow up (day 18) and visit 5- follow up (day 60).

Intervention Type

Drug

Phase

Phase IV

Drug/device/biological/vaccine name(s)

1. Ecomed (powder for oral suspension, azithromycin 100mg/5ml and lactulose 200mg/5ml, by JSC AVVA RUS, Russia) 2. Sumamed (powder for oral suspension, azithromycin 100mg/5ml, by Pliva Hrvatska doo, Croatia)

Primary outcome measure

The proportion of subjects with clinical improvement in the symptoms of the disease assessed by the researcher-clinician on the 4th day from the start of drug administration.

Efficacy is evaluated on the basis of the reduction and disappearance of the main subjective and objective symptoms of bacterial rhinosinusitis - the severity of difficulty in nasal breathing, the nature and severity of discharge from the nose, pain when palpating the projection of the paranasal sinuses, temperature reaction, headache, the presence and severity of general malaise.

Secondary outcome measures

1. Frequency and severity of symptoms of dysbiosis in the background of the studied therapy on the 4th, 17th day after the start of therapy.
2. Proportion of patients with persistent or worsening signs of infection on the 4th day from the start of treatment, requiring replacement of antibiotic therapy.
3. Assessment of gut microbial community diversity based on the assessment of the variability of 16S genes of ribosomal RNA on the 4th, 17th day from the start of therapy and the 60th day after completion of therapy compared to the initial level.
4. Frequency of adverse events, their severity and relationship with the studied therapy.

Overall study start date

01/11/2014

Completion date

25/01/2016

Eligibility

Key inclusion criteria

1. Outpatient patients of both sexes from 3 to 14 years.
2. Established diagnosis of Acute Purulent Sinusitis - evaluation of complaints, anamnesis, temperature, R-picture and rhinoscopy data - pus in the middle nasal passage and/or in the nasopharynx dome.
3. Ability to regularly receive the studied drugs and perform research procedures.
4. The Form of the Written Informed Consent to participate in the study is signed by one of the parents or the legal representative of the patient.
5. Informing the patients' parents that during the entire study period the patient should not take prebiotics, probiotics, synbiotics, sorbents.

Participant type(s)

Patient

Age group

Child

Lower age limit

3 Years

Upper age limit

14 Years

Sex

Both

Target number of participants

100

Key exclusion criteria

1. Intolerance to azalides, macrolides and other components of the drug.
2. Administration of antibacterial drugs, including sulfonamides, within 28 days before the start of screening.
3. Complicated course of infectious diseases of the upper and lower respiratory tract.
4. Bacterial infection of another location, requiring the administration of antibiotics.
5. Oncological disease without remission, at least for 5 years before the start of the study.
6. Epilepsy, febrile convulsions in history.
7. Impaired immunity according to anamnesis.
8. Immunodeficiency.
9. Active neoplastic process.
10. Any other serious illness or condition that could jeopardize patient safety, affect life expectancy, or hinder successful treatment or monitoring of a patient according to the protocol.
11. The reluctance of the child or his legal representatives to participate in clinical research.
12. Drug use, alcoholism, mental illness of the legal representative of the patient.
13. Participation in other clinical studies of medical drugs less than 3 months before the start of the study.

Date of first enrolment

21/04/2015

Date of final enrolment

18/11/2015

Locations

Countries of recruitment

Russian Federation

Study participating centre

Clinical Center 1, Children's City Polyclinic No. 133 of the Department of Health of Moscow

Smolnaya st., 55

Moscow

Russian Federation

117997

Sponsor information

Organisation

OJSC AVVA RUS

Sponsor details

Krylatsky holmy, 30, Bldg. 9

Moscow

Russian Federation

121614

+7 (495) 956-75-03

info@avva-rus.ru

Sponsor type

Industry

Website

<https://www.avva-rus.ru/>

Funder(s)

Funder type

Industry

Funder Name

MC Development, Russia.

Results and Publications

Publication and dissemination plan

Anticipated results of the study will be published in peer-review journals within 2019-2020. The microbiome post-treatment profile of the two treatment groups will be analysed and differences and similarities will be characterized. All patient information will remain anonymous.

It is anticipated that the Microbiome profile will be disseminated by publishing the results of the analysis in peer-review journal. No personal patient information will be disclosed but only the bacterial profile will be discussed that cannot be linked to any subject. Data that might be available as supplementary information in our publication will be the operational taxonomic unit (OTUs) that describes the microbiome profile in a given sample.

Intention to publish date

01/04/2019

Individual participant data (IPD) sharing plan

All data generated or analysed during this study will be included in the subsequent results publication

IPD sharing plan summary

Other